ORR 46%, CR 16%, CRi 27%, PR 3%DoR of CR/CRi, 2.3 mosMedian OS—6.2 mos→ Sorafenib with AZA, effective in relapsed AML ptswith FLT3-ITD (+). Here, FLT3 is linked to acute myeloid leukemia.